百时美施贵宝Bristol Myers Squibb Co. (BMY) 2011年年度报告「NYSE」.pdf

1、2011 ANNUAL REPORTInnovationInnovationgrowth throughYervoy patient and flight paramedic Bobby HarshOn the Cover:Yervoy(ipilimumab)patient and flight paramedic Yervoy(ipilimumab)patient and flight paramedic YervoyBobby Harsh first discovered a pimple on his face that wouldnt go away.It turned out to

2、be malignant mela-noma,the deadliest form of skin cancer.After 10 hours of facial reconstruction surgery and 90 stitches,the Maryland State Troopers battle for survival was just beginning.Even after an experimental vaccine and two rounds of an immunotherapy called interleukin-2,the cancer spread to

3、his lungs.“Being told you have a cancer that could kill you was very difficult,”he says more than two years later.“Once it metastasized,the odds were very slim I was going to live.”So Bobby,his wife and his three children decided to go on a long-planned camping trip to as many national parks as poss

4、ible.When he returned,he got the last slot in a clinical trial for an investigational drug called ipilimumab at the Blumenthal Cancer Center in Charlotte,North Carolina,five hours from his suburban Baltimore home.Still,he stopped making future plans:“I was preparing for the likelihood that I wasnt g

5、oing to be here in a year.”After just 12 weeks,his first scans showed major improvement.Today,still in the clinical trial and back to work,Bobby gets a checkup at Blumenthal every three months.Ipilimumab(now Yervoy)was approved for use in adults with Yervoy)was approved for use in adults with Yervoy

6、unresectable or metastatic melanoma in the U.S.in March 2011 and cleared for marketing in Europe in July.It is the first immunotherapy to deliver a signifi-cant long-term survival benefit in metastatic melanoma in a Phase III study.“You start looking at life differently,”Bobby admits.“When I work a